← Back to Search

Protease Inhibitor

VX-264 for Type 1 Diabetes

Phase 1 & 2
Recruiting
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will study a new treatment for type 1 diabetes to see if it is safe, well-tolerated, and effective.

Who is the study for?
This trial is for people with Type 1 Diabetes who have been managing their condition for over 5 years and are on a stable treatment plan. Participants must be using continuous glucose monitoring (CGM) consistently for at least a month before the study starts and agree to use it throughout the trial. Those who've had an islet cell or organ transplant, or cell therapy cannot join.
What is being tested?
The study tests VX-264's safety, how well participants can tolerate it, and its effectiveness in individuals with Type 1 Diabetes. The main goal is to see if this new intervention could potentially improve diabetes management.
What are the potential side effects?
While specific side effects of VX-264 aren't listed here, common concerns in trials like this may include reactions at injection sites, low blood sugar events, potential allergic reactions, and other unforeseen responses related to immune system changes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: VX-264Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Vertex Pharmaceuticals IncorporatedLead Sponsor
257 Previous Clinical Trials
35,052 Total Patients Enrolled

Media Library

VX-264 (Protease Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05791201 — Phase 1 & 2
Type 1 Diabetes Research Study Groups: VX-264
Type 1 Diabetes Clinical Trial 2023: VX-264 Highlights & Side Effects. Trial Name: NCT05791201 — Phase 1 & 2
VX-264 (Protease Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05791201 — Phase 1 & 2
~8 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top